Nevirapine Clearance After Short-term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT)
Nevirapine Plasma Level After Discontinuation of Short-term Antiretroviral Treatment for the Prevention of Mother-to-child Transmission of HIV and Development of Drug Resistant HIV-1 Variants With 1 or 2 Weeks Continuation of Zidovudine/Lamivudine in Women After Delivery
Sponsor: Chulalongkorn University
A NA clinical study on 3TC Related Mutation and NVP Plasma Level, this trial is completed. The trial is conducted by Chulalongkorn University and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2021 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
-
Aug 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
▶ Show 4 earlier versions
-
Nov 2018 — Aug 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chulalongkorn University
- Queen Savang Vadhana Memorial Hospital, Thailand
- Thai Red Cross AIDS Research Centre
For direct contact, visit the study record on ClinicalTrials.gov .